Bioinformatics is our DNA
We build tools to find challenging variants not detected by standard pipelines.
A key to providing clinical reports that deliver tangible patient benefits is the reliable and accurate detection of all the variants specific to the patient. Standard bioinformatic pipelines are effective in detecting frequently occurring variant types like SNP’s and Indels but fall short with variants such as Alu elements and mid-sized deletions.
Our bioinformatics team tirelessly develops tools that identify challenging variants, which are not addressed by best-of-breed open-source pipelines. To assist our team, we have brought together an ecosystem of experts, each familiar with a major disease and its bioinformatic challenges. This ecosystem allows us to tackle the vast majority of therapeutic and diagnostic areas. Read our whitepaper about challenging variant detection.
Our team has developed the tools to detect the following challenging variants:
Full list of variant types
- Mid-sized INDEL (~150b)
- Germline exome/WGS CNVs
- Somatic CNVs
- Structural Variants (SV)
- Alu elements
- Multi Nucleotide Variants (MNVs)
- Microsatellite instability (MSI)
- RGNA Gene Fusions
Challenging variants in constitutional diseases
Challenging variants are difficult to identify but play an important role in building a complete picture of a patient. These [...]Get whitepaper
A key component of our R&D strategy involves collaborating with research groups in academia and industry that contribute their expertise in specific therapeutic and diagnostic areas through collaborative research projects. As these projects progress, the resulting discoveries are often integrated into SeqOne’s bioinformatic stack, which further improves variant detection and accuracy.
If you are interested in collaborating with us on R&D projects, please contact us.
Some of our recent projects
- Improved automated variant ranking, in collaboration with the University of Grenoble Training Hospital.
- Use of whole genome data to improve the matching of kidney transplant donors and recipients, in collaboration with the University of Sorbonne.
- Analysis of a large DNA / RNA pan-cancer panel to deliver therapeutic recommendations, in collaboration with the Henri Baclesse Anti-Cancer Center.
Our latest scientific posts
6 May 2022
SeqOne posters at the ESHG; using ML and big data to improve variant interpretation
SeqOne will be at the ESHG show in Vienna in hall X4 booth 664. We will be presenting four posters hi lighting various projects by [...]
14 May 2020
Mobile element insertion (MEI) detection for NGS based clinical diagnostics
A growing number of scientific articles describe the pathogenic role of MEI’s, bringing a renewed focus on their importance in clinical diagnosis. Although NGS makes [...]
31 March 2020
Challenges and importance of mid-sized deletion identification for genomic medicine
The clinical importance of mid-sized deletions is becoming increasingly apparent with a growing number of variants of this type being identified as pathogenic in the [...]
15 October 2019
SeqOne nommée startup de l’année 2019 en Occitanie par Ernst & Young
SeqOne a été nommée startup de l’année pour l’édition 2019 du prix de l’”Entrepreneur de l’année” région Occitanie, proposé par Ernst & Young. Prochaine étape [...]
28 February 2018
Canadian and French startups announce genomics partnership to better diagnose rare disease
February 28th, 2018: Paris, France & Toronto, Canada Gene42 Inc., a Toronto company that develops software for precision medicine, and SeqOne, a French life [...]